Regulatory FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy Pharmaceutical TechnologyAstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-nave, high-risk NMIBC.OncologyRead full story pharminent June 1, 2026 (Last updated: June 1, 2026) Pharmaceutical Technology AstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-nave, high-risk NMIBC. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Previous PostNext: Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
